Heron Therapeutics, Inc. Announces Executive Changes
October 13, 2020 at 08:32 am EDT
Share
On October 13, 2020, Heron Therapeutics, Inc. announced that the Board of Directors of the Company elected Barry Quart, Pharm.D., age 63, as Chairman of the Board, effective October 13, 2020. Dr. Quart has served as Chief Executive Officer and as a director of the Company since 2012, and as President and Chief Executive Officer of the Company since 2019. The Company also announced the resignation of Dr. Quart as President and the promotion of John Poyhonen, age 60, previously Executive Vice President, Chief Commercial Officer, to the role of President and Chief Commercial Officer, each effective October 13, 2020. Dr. Quart will continue in his role as Chief Executive Officer. In connection with Dr. Quart’s election as Chairman of the Board, the independent directors of the Board appointed Craig Johnson to the role of Lead Independent Director, effective October 13, 2020. Mr. Johnson, age 58, has served as a director of the Company since 2014. The Company also announced the promotion of David Szekeres, age 47, previously Senior Vice President, Chief Legal, Business and Administrative Officer, to the role of Executive Vice President, Chief Operating Officer, effective October 13, 2020. Mr. Szekeres joined Heron as Senior Vice President, General Counsel, Business Development and Corporate Secretary in 2016 and was promoted to Chief Legal, Business and Administrative Officer in 2019. Additionally, the Company announced the retirement of Robert Hoffman, age 54, effective on October 16, 2020, the Company’s Senior Vice President, Finance and the Company’s principal financial officer and accounting officer (as defined under applicable securities laws) since 2017. Also, effective on October 13, 2020, the Company announced the promotion of Lisa Peraza, age 44, to the role of Vice President, Chief Accounting Officer and the Company’s principal financial officer and accounting officer (as defined under applicable securities laws).
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.